Tumor-Associated Glycans and Immune Surveillance
Open Access
- 16 June 2013
- Vol. 1 (2), 174-203
- https://doi.org/10.3390/vaccines1020174
Abstract
Changes in cell surface glycosylation are a hallmark of the transition from normal to inflamed and neoplastic tissue. Tumor-associated carbohydrate antigens (TACAs) challenge our understanding of immune tolerance, while functioning as immune targets that bridge innate immune surveillance and adaptive antitumor immunity in clinical applications. T-cells, being a part of the adaptive immune response, are the most popular component of the immune system considered for targeting tumor cells. However, for TACAs, T-cells take a back seat to antibodies and natural killer cells as first-line innate defense mechanisms. Here, we briefly highlight the rationale associated with the relative importance of the immune surveillance machinery that might be applicable for developing therapeutics.This publication has 192 references indexed in Scilit:
- Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpGCancer Immunology, Immunotherapy, 2012
- A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycansThe EMBO Journal, 2011
- ABO blood group and incidence of epithelial ovarian cancerInternational Journal of Cancer, 2010
- Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the artSeminars in Immunology, 2010
- Targeting anoikis resistance in prostate cancer metastasisMolecular Aspects of Medicine, 2010
- Recent development in carbohydrate-based cancer vaccinesCurrent Opinion in Chemical Biology, 2009
- Sialyl Lewis X Expression and Lymphatic Microvessel Density in Primary Tumors of Node-negative Colorectal Cancer Patients Predict Disease RecurrenceCancer Microenvironment, 2008
- NK gene complex dynamics and selection for NK cell receptorsSeminars in Immunology, 2008
- Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in miceCancer Immunology, Immunotherapy, 2007
- The Galα1,3Galβ1,4GlcNAc-R (α-Gal) epitope: A carbohydrate of unique evolution and clinical relevanceBiochimica et Biophysica Acta (BBA) - General Subjects, 2007